Why is Alivus Life falling/rising?

As of 29-Aug, Alivus Life Sciences Ltd is experiencing a decline in its stock price, currently at 941.30, which reflects a decrease of 3.7 points or 0.39%. The stock has underperformed its sector by 0.42% today and has been on a downward trend for the last three days, resulting in a total decline of 2.89% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment. Over the past week, the stock has dropped by 2.36%, and it has shown a significant decline of 7.82% over the past month, while its year-to-date performance is down by 4.82%. Despite a high return on equity (ROE) of 25.32% and a low debt-to-equity ratio, the company has faced challenges with poor long-term growth, as evidenced by its net sales and operating profit growth rates of only 4.49% and 2.26%, respectively, over the last five years.
Broader market context indicates that the Sensex has also faced a slight decline of 1.84% over the past week, but Alivus Life's performance has been notably worse, suggesting that specific company issues are contributing to its stock price drop. The stock's year-over-year return of -7.55% contrasts sharply with the Sensex's decline of only 2.83%, further highlighting the stock's underperformance. The falling investor participation, with a significant drop in delivery volume, suggests a lack of confidence among investors, which may be exacerbating the stock's decline. Overall, while the company has some positive attributes, the combination of poor growth prospects and recent performance trends has led to a negative sentiment surrounding Alivus Life Sciences Ltd.